|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NCLN |
Gene summary for NCLN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NCLN | Gene ID | 56926 |
| Gene name | nicalin | |
| Gene Alias | NET59 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q969V3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56926 | NCLN | P62T-E | Human | Esophagus | ESCC | 1.98e-31 | 7.43e-01 | 0.1302 |
| 56926 | NCLN | P65T-E | Human | Esophagus | ESCC | 6.69e-08 | 2.27e-01 | 0.0978 |
| 56926 | NCLN | P74T-E | Human | Esophagus | ESCC | 1.23e-17 | 5.67e-01 | 0.1479 |
| 56926 | NCLN | P75T-E | Human | Esophagus | ESCC | 2.93e-47 | 1.09e+00 | 0.1125 |
| 56926 | NCLN | P76T-E | Human | Esophagus | ESCC | 1.22e-13 | 3.73e-01 | 0.1207 |
| 56926 | NCLN | P79T-E | Human | Esophagus | ESCC | 1.54e-25 | 4.79e-01 | 0.1154 |
| 56926 | NCLN | P80T-E | Human | Esophagus | ESCC | 4.85e-26 | 8.53e-01 | 0.155 |
| 56926 | NCLN | P82T-E | Human | Esophagus | ESCC | 3.82e-15 | 7.96e-01 | 0.1072 |
| 56926 | NCLN | P83T-E | Human | Esophagus | ESCC | 6.17e-26 | 9.29e-01 | 0.1738 |
| 56926 | NCLN | P89T-E | Human | Esophagus | ESCC | 6.65e-15 | 9.53e-01 | 0.1752 |
| 56926 | NCLN | P91T-E | Human | Esophagus | ESCC | 1.63e-16 | 1.83e+00 | 0.1828 |
| 56926 | NCLN | P104T-E | Human | Esophagus | ESCC | 9.57e-05 | 5.30e-01 | 0.0931 |
| 56926 | NCLN | P107T-E | Human | Esophagus | ESCC | 1.28e-41 | 9.72e-01 | 0.171 |
| 56926 | NCLN | P126T-E | Human | Esophagus | ESCC | 8.94e-06 | 4.57e-01 | 0.1125 |
| 56926 | NCLN | P127T-E | Human | Esophagus | ESCC | 1.15e-06 | 7.47e-02 | 0.0826 |
| 56926 | NCLN | P128T-E | Human | Esophagus | ESCC | 3.95e-31 | 8.97e-01 | 0.1241 |
| 56926 | NCLN | P130T-E | Human | Esophagus | ESCC | 4.10e-42 | 8.14e-01 | 0.1676 |
| 56926 | NCLN | HCC1_Meng | Human | Liver | HCC | 4.28e-42 | 4.59e-02 | 0.0246 |
| 56926 | NCLN | HCC2_Meng | Human | Liver | HCC | 1.87e-29 | 1.92e-01 | 0.0107 |
| 56926 | NCLN | HCC2 | Human | Liver | HCC | 1.93e-02 | 3.07e+00 | 0.5341 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0043254 | Colorectum | AD | regulation of protein-containing complex assembly | 148/3918 | 428/18723 | 2.64e-11 | 3.18e-09 | 148 |
| GO:0031647 | Colorectum | AD | regulation of protein stability | 108/3918 | 298/18723 | 6.33e-10 | 5.08e-08 | 108 |
| GO:0050821 | Colorectum | AD | protein stabilization | 73/3918 | 191/18723 | 3.02e-08 | 1.64e-06 | 73 |
| GO:00432541 | Colorectum | SER | regulation of protein-containing complex assembly | 119/2897 | 428/18723 | 3.34e-11 | 5.86e-09 | 119 |
| GO:00316471 | Colorectum | SER | regulation of protein stability | 86/2897 | 298/18723 | 2.56e-09 | 2.42e-07 | 86 |
| GO:00508211 | Colorectum | SER | protein stabilization | 58/2897 | 191/18723 | 1.46e-07 | 8.59e-06 | 58 |
| GO:00316472 | Colorectum | MSS | regulation of protein stability | 103/3467 | 298/18723 | 2.52e-11 | 3.49e-09 | 103 |
| GO:00432542 | Colorectum | MSS | regulation of protein-containing complex assembly | 130/3467 | 428/18723 | 1.38e-09 | 1.03e-07 | 130 |
| GO:00508212 | Colorectum | MSS | protein stabilization | 68/3467 | 191/18723 | 1.53e-08 | 8.81e-07 | 68 |
| GO:00432544 | Colorectum | FAP | regulation of protein-containing complex assembly | 101/2622 | 428/18723 | 5.18e-08 | 4.07e-06 | 101 |
| GO:00508214 | Colorectum | FAP | protein stabilization | 51/2622 | 191/18723 | 2.63e-06 | 9.96e-05 | 51 |
| GO:00316474 | Colorectum | FAP | regulation of protein stability | 70/2622 | 298/18723 | 6.60e-06 | 2.04e-04 | 70 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
| GO:003164722 | Liver | HCC | regulation of protein stability | 211/7958 | 298/18723 | 2.29e-23 | 5.01e-21 | 211 |
| GO:005082122 | Liver | HCC | protein stabilization | 139/7958 | 191/18723 | 1.61e-17 | 1.71e-15 | 139 |
| GO:004325422 | Liver | HCC | regulation of protein-containing complex assembly | 264/7958 | 428/18723 | 5.47e-16 | 4.39e-14 | 264 |
| GO:003164720 | Oral cavity | OSCC | regulation of protein stability | 193/7305 | 298/18723 | 1.30e-19 | 1.95e-17 | 193 |
| GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NCLN | deletion | Frame_Shift_Del | novel | c.1623delN | p.Ala542LeufsTer17 | p.A542Lfs*17 | Q969V3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| NCLN | SNV | Missense_Mutation | c.52C>G | p.Leu18Val | p.L18V | Q969V3 | protein_coding | tolerated(0.13) | benign(0.012) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NCLN | SNV | Missense_Mutation | c.248N>A | p.Arg83His | p.R83H | Q969V3 | protein_coding | tolerated(0.18) | possibly_damaging(0.482) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NCLN | SNV | Missense_Mutation | c.1207C>T | p.Arg403Trp | p.R403W | Q969V3 | protein_coding | deleterious(0.02) | probably_damaging(0.923) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NCLN | SNV | Missense_Mutation | c.791N>T | p.Thr264Met | p.T264M | Q969V3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D5-6924-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NCLN | SNV | Missense_Mutation | c.802T>A | p.Tyr268Asn | p.Y268N | Q969V3 | protein_coding | deleterious(0.01) | possibly_damaging(0.837) | TCGA-G4-6314-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD | |
| NCLN | SNV | Missense_Mutation | novel | c.1660C>A | p.Gln554Lys | p.Q554K | Q969V3 | protein_coding | tolerated(1) | benign(0.086) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NCLN | SNV | Missense_Mutation | rs564407893 | c.637N>A | p.Gly213Arg | p.G213R | Q969V3 | protein_coding | tolerated(0.37) | benign(0.081) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NCLN | SNV | Missense_Mutation | c.1120C>T | p.Arg374Cys | p.R374C | Q969V3 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
| NCLN | SNV | Missense_Mutation | novel | c.1144N>A | p.Ala382Thr | p.A382T | Q969V3 | protein_coding | deleterious(0) | possibly_damaging(0.84) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |